FDA pulls up Aurobindo Pharma for 'repeated' failures in CGMP

The FDA recently issued a letter warning the drug- makers unit X1 in Srikakulam district of Andhra Pradesh for deviations from CGMP for API.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2Nwx4BJ
via IFTTT